Journals / Bezmiâlem Science / 2018 / Cilt: 6 - Sayı: 4

The World Anti-Doping Code: Truths and Wrongs

Dünya Antidoping Şifresi: Doğrular ve Yanlışlar

Pages
301–304
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also the prohibition/allowanceof beta blockers and alcohol in some sports were criticized in thepresent paper.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:World Anti Doping Agency (WADA) is the unique authorityto set the rules of doping and banned substances all around theWorld and the prohibited list is annually updated.
📊
Key Findings & Data:It aims toprevent the use of the compounds that may increase athletic per-formance, hence create a fair and equal status for all competitorsand also protect athlete’s health from the unexpected or side ef-fects of the compounds that have a potential for misuse.
💡
Conclusion & Impact:Also the prohibition/allowanceof beta blockers and alcohol in some sports were criticized in thepresent paper.
🔬Design:Review & Systematic Survey
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

World Anti Doping Agency (WADA) is the unique authorityto set the rules of doping and banned substances all around theWorld and the prohibited list is annually updated. It aims toprevent the use of the compounds that may increase athletic per-formance, hence create a fair and equal status for all competitorsand also protect athlete’s health from the unexpected or side ef-fects of the compounds that have a potential for misuse. Thelist of 2018 consists three major titles of prohibited substancesand methods. Prohibited substances are classified as “S” code,whereas prohibited methods as “M” and substances prohibitedin particular sports as “P.” The present review criticize some il-logical parts of the 2018 prohibited list. For example; despite themost of the beta-2 agonists, diuretics/masking agents and stimu-lants were banned, a few of them are not accepted as doping inthe use of limited doses. Some compounds that have a seriouspotential to increase mood and physical resistance similar to am-phetamines, such as MAO inhibitors and anticholinergics havenot been banned yet by WADA. Also the prohibition/allowanceof beta blockers and alcohol in some sports were criticized in thepresent paper.

Özet

Dünya Anti Doping Ajansı (WADA), doping ve yasaklı mad- deler konusunda Dünya’daki kuralları belirleyen tek otorite olup, yasaklı maddeleri içeren listesini her yıl güncellemektedir. Buradaki amaç, atletik performans artışı yapan maddelerin kul- lanımını önlemek ve böylece tüm yarışmacılara eşit ve adil bir ortam yaratmak yanında, kötüye kullanım potansiyeli taşıyan bu maddelerin sebep olabileceği beklenmeyen ve istenmeyen etki- lerinden sporcuları korumaktır. 2018 yasaklı maddeler ve me- todlar listesi üç alt başlıktan oluşmaktadır. Yasaklı maddeler “S” kodu ile sınıflandırılmışken, yasaklı metodlar “M”, bazı özel spor branşlarındaki yasaklılar ise “P” ile sınıflandırılmıştır. Bu derle- mede WADA 2018 yasaklılar listesindeki mantıksız uygulama ve talimatlar eleştirilmektedir. Örneğin; birçok beta-2 agonist, diüretik/maskeleyici ajanlar ve uyarıcı maddeler yasaklanmış ol- masına ragmen, bu gruplardan az sayıda maddenin limitli kulla- nımına izin verilmektedir. MAO inhibitörleri ve antikolinerjik- ler gibi, amfetamin benzeri şekilde ruhsal durumu yükselten ve fiziksel dayanıklılığı arttıran maddeler WADA tarafından henüz yasaklanmamıştır. Ayrıca beta blokerler ve alkolün bazı branşlar- da serbest, bazılarında ise yasaklı olması da tartışılmıştır.

🔖

Cite This Article

GEPDİREMEN, A. (2022). The World Anti-Doping Code: Truths and Wrongs. Bezmiâlem Science, Cilt: 6 - Sayı: 4, 301–304. https://ajindex.com/articles/464137

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Gepdiremen A. Uzman Görüş: Ergojenikler ve doping. Türkiye Cimnastik Federasyonu Bülteni 2016
  2. Fuso L, Mores N, Valente S, Malerba M, Montuschi P. Long act- ing beta-agonists and their associations with inhaled corticosteroids with COPD. Curr Med Chem 2013
  3. [CrossRef] Koch S, Karacabeyli D, Galts C, MacInnis MJ, Sporer BC, Koehle MS. Effects of inhaled bronchodilatators on lung func- tion and cycling performance in female athletes with and with- out exercise-induced bronchoconstruction. J Sci Med Sport 2015
  4. [CrossRef] Carlsen KH, Hem E, Strensrud T, Held T, Herland K, Mow- inckel P. Can asthma treatment in sports be doping? The effect of the rapid onset, long acting inhaled beta-2 agonist for- moterol upon endurance performance in healthy, well trained athletes. Respir Med 2001
  5. [CrossRef] Elers J, Mørkeberg J, Jansen T, Belhage B, Backer V. High dose inhaled salbutamol has no acute effects on aerobic capacity or oxygen uptake kinetics in healthy trained men. Scand J Med Sci Sport 2012
  6. [CrossRef] Hostrup M, Kalsen A, Bangsbo J, Hemmersbach P, Karlsson S, Backer V. High dose inhaled terbutaline increases muscle strength and enhances maximal sprint performance in trained men. Eur J Appl Physiol 2014
  7. [CrossRef] Hostrup M, Kalsen A, Ortenblad N, Juel C, Mørch K, Rzeppa S, et al. β2-adrenergic stimulation enhances Ca2+ release and contractile properties of skeletal muscles, and counteracts ex- ercise-induced reductions in Na+-K+-ATPase Vmax in trained men. J Physiol 2014
  8. [CrossRef] Decorte N, Bachasson D, Guinot M, Flore P, Levy P, Verges S, et al. Effect of salbutamol on neuromuscular function in endurance athletes. Med Sci Sports Exerc 2013
  9. [CrossRef] Kalsen A, Hostrup M, Bangsbo J, Backer V. Combined inhala- tion of beta-2 agonists improves swim ergometer sprint perfor- mance but not high-intensity swim performance. Scand J Med Sci Sports 2014
  10. [CrossRef] Jacobson GA, Yee KC, Wood-Baker R, Walters EH. SULT 1A3 single nucleotide polymorphism and the single dose pharmacoci- netics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels. Drug Test Anal 2015
  11. [CrossRef] Kim SH, Ye YM, Lee HY, Sin HJ, Park HS. Combined phar- macogenetic effect of ADCY9 and ADRB2 gene polymor- phisms on the bronchodilatator response to inhaled combina- tion therapy. J Clin Pharm Ther 2011
  12. [CrossRef] Dinger J, Bardenhe